THE PARTNERS

 

Name of the coordinating person: Dr. Bruno AMATI

 
  • ITALIAN INSTITUTE OF TECHNOLOGY (IIT)
    ITALY
    Bruno AMATI, Oncogenes, Chromatin and Cell Cycle Control
     
    IIT logo Since July 2013, Bruno AMATI team is affiliated to the Italian Institute of Technology (IIT) which makes IIT the new coordinating organization of MODHEP.

    IIT is a foundation established jointly by the Italian Ministry of Education, University and Research and the Ministry of Economy and Finance, whose headquarters are based in Genova. The Center for Genomic Science of IIT is an outstation of the Italian Institute of Technology and is located at the IFOM-IEO Campus in Milan. Together, the three institutions present in the Campus (IFOM, IEO and the IIT Center) constitute the prime Cancer Research environment in Italy.

  • European Institute of Oncology (IEO)
    ITALY
    Gioacchino NATOLI, Transcriptional control in inflammation and cancer
    Francesca CICCARELLI, Bioinformatics and Evolutionary Genomics of Cancer
     
    IEO logo
     
    The European Institute of Oncology (IEO) is an independent, nonprofit biomedical research institution and one of the 8 Ministry of Health-designated/ comprehensive cancer centres in Italy. In addition to providing patients with the best care available, IEO is committed to cutting-edge research in oncology, ranging from basic to translational research and clinical trials.

    Bruno Amati has been acting as the Coordinator of MODHEP Consortium from the project start in 2011 and has lead one of the three research groups involved in MODHEP at IEO. Since July 2013, his team is affiliated to the Italian Institute of Technology (IIT) which makes IIT the new coordinating organization of MODHEP.

  • INSTITUT CURIE (CURIE)
    FRANCE
    Edith HEARD, Developmental Biology and Genetics
    Geneviève ALMOUZNI
     
    INSTITUT CURIE logo The Institut Curie is an internationally recognized research center of excellence in Europe dedicated to cancer research at the interface between cutting-edge basic research and innovative healthcare. The IC Research center and the Hospital are on the same campus providing unique opportunities for translational research. The IC hosts leading experts in several areas including Epigenetics (Almouzni andHeard), Cancer, Immunology and Developmental and Cellular Biology. The Genetics and Developmental Biology Joint Research Unit consists of seven internationally competitive research teams working on the simple, but fundamental, concept that an understanding of normal developmental regulation should provide us with a better understanding of the basis of human pathology.
  • THE INSTITUTE OF GENETICS AND MOLECULAR MEDICINE (UEDIN IGMM)
    UNITED KINGDOM
    Wendy BICKMORE
     
    IGMM logo

    The Institute of Genetics and Molecular Medicine is an exciting development in Edinburgh bringing together the MRC Human Genetics Unit, the Molecular Medicine Centre and the Edinburgh Cancer Research Centre. With over 500 research and support scientists, IGMM is one of the largest centres for human genetics and molecular medicine, both in the UK and internationally.

    Together, IGMM has critical mass in many key areas, including: cell and molecular biology, biochemistry, developmental biology, human genetics, statistical genetics, model organisms, computational biology, pathology, public health and epidemiology and clinical trials. Furthermore IGMM's strengthened links with NHS doctors gives access to key patient cohorts and clinical expertise.

    The Bickmore lab will use three-dimensional FISH to measure changes in chromatin compaction at genomic regions subject to changes in gene expression or epigenetic modifications in liver cancer.

  • HUBRECHT INSTITUTE (KNAW)
    THE NETHERLANDS
    Wouter de LAAT
     
    hubrecht logo The Hubrecht Institute is a research institute of the Royal Netherlands Academy of Arts and Sciences (KNAW) and performs research in the field of developmental biology and stem cell research.
    The de Laat group has made seminal contributions to the field of nuclear organization. They were the first to adapt and apply 3C technology to mammalian systems and to show that in living cells functional chromatin loops are being formed between enhancers and genes. They revealed that transcription factors shape the genome and they developed the first genome-wide screening method (4C technology) for DNA interactions. They are considered world-wide experts on 3C based technologies for mapping of the 3D genome.
  • FONDAZIONE TELETHON (FTELE)
    ITALY
    Diego Di BERNARDO
     
    FONDAZIONE TELETHON DTI logo TIGEM logo Valerio Orlando's leads the Telethon laboratory of Epigenetics and Genome Reprogramming at IRCCS Santa Lucia (Rome, Italy), Italy's top ranked hospital specialized in neurorehabilitation. Dr. Orlando is studying chromatin based epigenetic mechanisms that control cell identity and reprogramming. Dr Orlando has top expertise in Epigenetics and Chromatin research.

    Valerio ORLANDO team moved from FTELE to FSL (Fondazione Santa Lucia) in January 2013. FTELE remains a MODHEP partner because of Diego DI BERNARDO team there. This new transfer just resulted in the addition of a new partner to MODHEP consortium.

  • SANTA LUCIA FOUNDATION (FSL)
    ITALY
    Valerio ORLANDO
     
     Santa Lucia Foundation logo As of January 2013, Valerio Orlando team moved from FTELE (Fondazione Telethon) to the Santa Lucia Foundation (FSL) located in Rome which became as a result MODHEP partner n15.

    Since 1992, FSL (Fondazione Santa Lucia) has been recognized by the Italian Ministry of Health as a Scientific Institute for Research, Hospitalization and Health Care because of its activity related to neurosciences and neuro-rehabilitation. The Institute is equipped with many laboratories for epidemiological, diagnostic-instrumental, genetic and molecular-biological studies of diseases that cause neurological disabilities.

  • MATER MEDICAL RESEARCH INSTITUTE (MMRI)
    AUSTRALIA
    Geoff FAULKNER, Genome Plasticity and Disease Group
     
    MMRI logo

    Mater Medical Research Institute is a non-profit world class research institute that is committed to academic medicine and aims to discover, develop, translate, and commercialise medical research that integrates with relevant areas of excellence within clinical practice. From babies to adults, MMRI helps the community lead healthy lives. MMRI works to uphold the values of its founders, the Sisters of Mercy. Nestled within Mater’s world-class hospitals at South Brisbane, its close proximity allows a unique ability to successfully combine medical research with clinical practice, helping deliver the best outcomes for patients, staff and the wider community.

    The core focus of the Genome Plasticity and Disease group at MMRI is to discover spontaneous mutations (those not inherited from parents) that occur in the somatic cells of the body and cause cancer. In particular, this group is interested in retrotransposons, a type of "jumping gene" that moves to a new genomic location and changes how that region functions. To study these elements, a combination of high-throughput DNA sequencing, computational biology and experimental validation are used.

    Dr. Faulkner's research will involve bioinformatics analysis of the genetic data that MODHEP produces, in particular looking at the regulation and control of retrotransposons during liver cancer.

  • BABRAHAM INSTITUTE (BABRAHAM)
    UNITED KINGDOM
    Peter FRASER
     
    BABRAHAM logo The Babraham Institute is an internationally renowned research institute undertaking innovative scientific research to discover the molecular mechanisms that underlie normal cellular processes and functions, and how their failure or abnormality may lead to disease. Two themes are central to our research remit: epigenetics & chromatin - how the genome is regulated without change to the DNA sequence of genes, and how 3D genome organization contributes to controlling gene expression. Fraser's group was first to show long-range chromatin interactions between genes and distal enhancers, first to demonstrate interchromosomal interactions in mammals, and first to demonstrate preferential sharing of transcription factories by co-regulated genes.
  • WEIZMANN INSTITUTE OF SCIENCE (WIZ)
    ISRAEL
    Amos TANAY
     
    WEIZMANN logo The Tanay group at the Weizmann Institute is working to define and expand the innovative field of computational epigenomics. The Weizmann Institute of Science (WIS) is a centre of excellence in scientific research,with a strong tradition of interdisciplinary research and systems biology. Home to over 250 research groups working in biology, chemistry, physics and mathematics, the Institute have establish a powerful community of quantitative and systems biologists which stimulate innovation by maximizing interaction and allowing free flow of ideas between theoretical/computational and experimental work.
  • RIKEN (RIKEN)
    JAPAN
    Piero CARNINCI
     
    RIKEN logo The Omics Science Center (OSC) is at the RIKEN Yokohama Institute, a part of RIKEN. RIKEN is an abbreviation “The Institute for the Physical and Chemical Research” OSC has developed CAGE (cap-analysis gene expression) technologies and exploited them in the FANTOM projects.
  • INSTITUT PASTEUR (IP)
    FRANCE
    Yu WEI
     
    INSTITUT PASTEUR logoInstitut Pasteur is a private non-profit foundation dedicated to research, education and public health. Since its creation by Louis Pasteur in 1887, Institut Pasteur has always been committed to both basic research and its applications in battling human diseases. It is recognized today as one of the world's leading biomedical research centres. Nine scientists of Institut Pasteur have been awarded the Nobel Prize for medicine and physiology.
  • INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    FRANCE
    Didier SAMUEL
    Jamila FAIVRE
    Marie-Annick BUENDIA
     
    INSERM logoINSERM logoHOPITAUX logo The National Institute for Health and Medical Research (INSERM) is a public scientific and technological organization. INSERM's vocation is to promote health for all. It is by stressing and nourishing the continuum between the different fields of research in fundamental biology, cognitive and applied medicine and public health that INSERM meets its overriding objectives, which are to improve our understanding of human diseases, and to ensure that patients, the medical community, and our national and international partners benefit rapidly from the latest research findings. The Joint Research Unit 785 INSERM/University Paris XI involved in MODHEP is located at the HepatoBiliary Centre (HBC) of the Paul-Brousse Hospital. The HBC is the reference clinical institute for liver diseases in France.
  • BIOBYTE SOLUTIONS GMBH (BIOBYTE)
    GERMANY
    Ivica LETUNIC
     
    Biobyte logo Biobyte Solutions GmbH is a provider of customized bioinformatics services and tools. Founded in 2008 by some of the leading European scientists in the bioinformatics field, biobyte solutions is oriented towards the development of novel biocomputational tools. Company also provides various bioinformatics services, from data analysis and integration, to database maintenance and development.
  • NOVAMEN (NOVAMEN)
    FRANCE
     
    NOVAMEN logo NOVAMEN is a brand of ACIES Consulting Group which is active on the national and European stage by supporting collaborative research programs bringing together private and public stakeholders. Since 14 years, NOVAMEN has supported 130 consortia from various fields (health, ITC, environment, food, energy etc.) in the setting-up of proposals.

    What does Novamen do on MODHEP project?

    NOVAMEN is part of MODHEP consortium as management partner. Its role is to support the coordinator from an operational point of view in its management-related tasks, from the consortium coordination, the deliverables follow-up up to the production of contractual activity and financial reports.NOVAMEN also takes part in the development of dissemination actions such as newsletters, leaflets, workshops, symposium to foster the project visibility and communicate on its results towards the scientific and general public audience.